Chemomab Therapeutics (CMMB) News Today $1.60 -0.04 (-2.44%) (As of 11:50 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024November 20 at 2:32 PM | markets.businessinsider.comChemomab Therapeutics Aligns Leadership Incentives with ShareholdersNovember 19 at 3:50 PM | markets.businessinsider.comOral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisNovember 19 at 7:00 AM | globenewswire.comChemomab Therapeutics' (CMMB) "Outperform" Rating Reiterated at OppenheimerNovember 18 at 2:47 AM | americanbankingnews.comChemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy RatingNovember 15, 2024 | markets.businessinsider.comRoth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)November 15, 2024 | markets.businessinsider.comChemomab Therapeutics sees cash runway through beginning of 2026November 14, 2024 | markets.businessinsider.comChemomab’s Positive Trial Results Boost Investor ConfidenceNovember 14, 2024 | markets.businessinsider.comChemomab Therapeutics (CMMB) Set to Announce Quarterly Earnings on ThursdayNovember 13, 2024 | americanbankingnews.comChemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business UpdateOctober 30, 2024 | markets.businessinsider.comChemomab Therapeutics to Present at October 2024 Investor ConferencesOctober 1, 2024 | stockhouse.comChemomab Therapeutics (CMMB) Gets a Buy from OppenheimerAugust 22, 2024 | markets.businessinsider.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024August 21, 2024 | investorplace.comChemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 21, 2024 | globenewswire.comChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business UpdateAugust 12, 2024 | finance.yahoo.comChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business UpdateAugust 12, 2024 | globenewswire.comChemomab Therapeutics Announces Closing of $10 Million Private PlacementJuly 30, 2024 | globenewswire.comChemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementJuly 26, 2024 | globenewswire.comChemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital RaiseJuly 25, 2024 | finance.yahoo.comChemomab falls on private placement despite mid-stage win for lead assetJuly 25, 2024 | msn.comChemomab Reports Positive Results For Phase 2 Trial Of CM-101July 25, 2024 | markets.businessinsider.comChemomab Collapses on Private PlacementJuly 25, 2024 | msn.comChemomab Therapeutics Announces $10 Million Private PlacementJuly 25, 2024 | globenewswire.comChemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing CholangitisJuly 25, 2024 | globenewswire.comChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceJune 6, 2024 | globenewswire.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 17, 2024 | globenewswire.comMaxim Group Initiates Coverage of Chemomab Therapeutics - Depositary Receipt () (CMMB) with Buy RecommendationMay 14, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)May 10, 2024 | markets.businessinsider.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024May 9, 2024 | investorplace.comChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleMay 8, 2024 | globenewswire.comChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceMay 2, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 24, 2024 | globenewswire.comChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisApril 18, 2024 | globenewswire.comChemomab Therapeutics Ltd. (CMMB)April 8, 2024 | finance.yahoo.comChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024April 2, 2024 | globenewswire.comChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisMarch 25, 2024 | globenewswire.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023March 7, 2024 | investorplace.comChemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 7, 2024 | finanznachrichten.deChemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 7, 2024 | finance.yahoo.comChemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceMarch 5, 2024 | prnewswire.comBiotech Shares Massively Bid Up Before Opening BellFebruary 20, 2024 | msn.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | finance.yahoo.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | prnewswire.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | finance.yahoo.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | prnewswire.comChemomab Therapeutics to Participate in Upcoming Investor ConferencesFebruary 5, 2024 | finance.yahoo.comChemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisJanuary 30, 2024 | finance.yahoo.comChemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and DatesJanuary 6, 2024 | benzinga.comChemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024January 3, 2024 | finance.yahoo.com Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO CMMB Media Mentions By Week CMMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMMB News Sentiment▼0.410.47▲Average Medical News Sentiment CMMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMMB Articles This Week▼91▲CMMB Articles Average Week Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NVCT News Today ASRT News Today PYRGF News Today PWUP News Today IVVD News Today GBIO News Today GNTA News Today SLS News Today QNCX News Today RLMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMMB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
